Summary
The authors performed an experimental study on myocardial injury induced by tyramine. For this purpose Sprague-Dawley male rats received multiple dose levels of tyramine hydrochloride. The drug exerts its sympathomimetic effects chiefly by the release of catecholamines stored in nerve endings. Myocardial lesions were documented on the basis of serum creatinkinase isoenzyme (MB-CK) changes and creatinkinase activity (CK) depletion in homogenate of cardiac tissue in animals sacrificed at different time intervals from tyramine injection.
Accordingly, MB-CK values expressed as IU/l×103 (mean±standard error of the mean, [SEM]) assessed at the 2nd and 4th hours from 50, 100, or 150 mg i.p. tyramine/100 g body weight were 0.99±0.23 or 0.85±0.30 (50 mg), 1.75±0.24 or 8.50±0.41 (100 mg), 2.07±0.60 or 8.40±0.39 (150 mg), respectively. Values in control animals were 0.51±0.07. As shown, the most marked increase in MB-CK levels is obtained at the 4th hour in 100 mg/100 g b.w. tyramine-treated rats. Thus MB-CK values were also explored at the 6th (7.43±0.15) and 12th (2.24±0.23) hours from drug administration. A significant (p<0.001) rise in serum MB-CK levels can be observed reaching the peak at the 4th hour after tyramine (100 mg/100 g b.w.).
Moreover, the CK myocardial content (IU/mg of protein) in the same tyramine-animals at the 2nd or 4th hours from 50, 100 or 150 mg of the i.p. drug/100 g b.w. were (mean ± SEM) 11.10±0.05 or 9.26±0.57 (50 mg), 9.42±0.81 or 8.57±0.22 (100 mg), 8.92±2.17 or 6.70±0.04 (150 mg), respectively. At the 6th or 12th hours from i.p. tyramine (100 mg/100 g b.w.) CK values were 9.60±0.48 or 9.99±0.56. Control values showed 13.50±0.68. A significant (p<0.001) decrease in CK myocardial content in the rats treated by the drug was achieved with the most marked CK depletion 4 hours after receiving tyramine (100 mg/100 g b.w.).
On these bases, the ultrastructural changes were investigated in tyramine-treated rats (100 mg/100 g b.w.) at the 4th hours from the drug administration. The finding included mitochondrial and myofibrillar damage.
In conclusion, this experimental model accounts for the possibility to induce myocardial damagein vivo in tyramine-treated rats.
Similar content being viewed by others
References
Bhagat, B., J. Jr. Gilliam: Factors influencing the depletion of cardiac norepinephrine by tyramine. J. Pharmacol. Exp. Ther.153, 191–196 (1966).
Borda, L., R. Shuchleib, P. D. Henry: Effect of potassium on isolated canine coronary arteries. Modulation of adrenergic responsiveness and release of norepinephrine. Circulat. Res.41, 778–786 (1977).
Burn, J. H., M. J. Rand: The action of sympathomimetic amines in animals treated with reserpine. J. Physiol. (London)144, 314–336 (1958).
Carlsson, A.: Pharmacological depletion of catecholamines stores. Pharmacol. Rev.18, 541–549 (1966).
Chiariello, M., G. Brevetti, G. De Rosa, R. Acunzo, F. Petito, F. Rengo, M. Condorelli: Protective effects of simultaneous alpha and beta adrenergic receptor blockade on myocardial cell necrosis after coronary arterial occlusion in rats. Amer. J. Cardiol.46, 249–254 (1980).
Duff, G. L., J. D. Hamilton, D. Magner: Experimental production of arteriolonecrosis and medionecrosis of arteries by means of tyramine injections. Proc. Soc. Exp. Biol. (N.Y.)41, 295–297 (1939).
Furchgott, R., P. S. Garcia: Effects of inhibition of norepinephrine, tyramine and other drugs on guinea-pig left atrium. J. Pharmacol. Exp. Ther.163, 98–122 (1968).
Genovese, A., M. Chiariello, G. Ferro, A. A. Cacciapuoti, M. Condorelli: Myocardial hypertrophy in the rat. Correlation between two experimental models. Jpn. Heart J.21, 511–518 (1980a).
Genovese, A., M. Chiariello, S. Latte, W. De Alfieri, A. A. Cacciapuoti, M. Condorelli: Effects of antiplatelet and calcium antagonist drug on infarct size in rats. Acta Cardiol.35, 419–427 (1980b).
Gornall, A. G., C. J. Bardowill, M. M. David: Determination of serum proteins by means of the biuret reaction. J. Biol. Chem.177, 751–756 (1949).
Haft, J. I., P. Krantz, F. Albert, K. Fani: Intravascular platelet aggregation in the heart induced by norepinephrine: microscopic studies. Circulation46, 698–708 (1972).
Jamieson, D. D., K. M. Taylor: Non specific stimulant activity of tyramine on isolated intestinal preparations. Agent Actions9, 422–427 (1979).
Janke, J., W. Jaedicke, A. Fleckenstein: Prevention of isoproterenol-induced cardiac necrosis by reduction of transmembrane Ca influx inhibitors of excitation-contraction coupling. Plüg. Arch. ges. Physiol.R8, 319–333 (1970).
Kjekshus, J. K., B. E. Sobel: Depressed myocardial creatine phosphokinase activity following experimental myocardial infarction in rabbit. Circulat. Res.27, 403–414 (1970).
MacLean, D., M. C. Fishebein, E. Braunwald, P. R. Maroko: Long-term preservation of ischemic myocardium after experimental coronary occlusion. J. Clin. Invest.61, 541–551 (1978).
Maling, H. M., B. Highman, E. C. Thompson: Some similar effects after large doses of catecholamines and myocardial infarction in dogs. Amer. J. Cardiol.5, 628–633 (1960).
Moss, A. J., I. Vittands, E. A. Schenk: Cardiovascular effects of sustained norepinephrine infusion. I. Hemodynamics. Circulat. Res.18, 596–604 (1966).
Muscholl, E.: Indirectly acting sympathomimetic amines. Pharmacol. Rev.18, 551–559 (1966).
Rona, G., C. I. Chappel, T. Balazs, R. Gaudry: An infarct-like myocardial lesion and other toxic manifestations produced by isoproterenol in the rat. Arch. Path.67, 443–455 (1959).
Rosemblum, I., A. Wohl, A. A. Atein: Studies in sympathomimetic amines. Toxicol. Appl. Pharmacol.7, 1–8 (1965).
Schenk, E. A., A. J. Moss: Cardiovascular effects of sustained norepinephrine infusion. II. Morphology. Circulat. Res.18, 605–615 (1966).
Smith, A. D.: Mechanisms involved in the release of noradrenaline from sympathetic nerves. Brit. Med. Bull.29, 123–129 (1973).
Snedecor, G. W., W. G. Cochran: Statistical methods. Iowa State University Press. Iowa City. (1967).
Sobel, B. E., R. Roberts, B. K. Larson: Estimation of infarct size from serum MB creatinephosphokinase activity: applications and limitations. Amer. J. Cardiol.37, 474–485 (1976).
Somlyo, A. P., A. V. Somlyo: Vascular smooth muscle. II. Pharmacology of normal and hypertensive vessels. Pharmacol. Rev.22, 276–278 (1970).
Szakacs, J. E., A. Cannon: L-norepinephrine myocarditis. Amer. J. Clin. Path.30, 425–434 (1958).
Szakacs, J. E., B. Mehlman: Pathologic changes induced by l-norepinephrine. Quantitative aspects. Amer. J. Cardiol.5, 619–627 (1960).
Toda, N., S. Hayashi, K. Hattori: Analysis of the effect of tyramine and norepinephrine in isolated canine cerebral and mesenteric arteries. J. Pharmacol. Exp. Ther.205, 382–391 (1978).
Trendelenburg, U.: Supersensitivity and subsensitivity to sympathomimetic amines. Pharmacol. Rev.15, 225–276 (1963).
Waldestrom, A. P., A. C. Hjalmarson, L. Thornell: a possible role of noradrenaline in the development of myocardial infarction. Amer. Heart J.95, 43–51 (1978).
Weiner, N., P. R. Draskoczy, W. R. Burac: The ability of tyramine to liberate catecholaminesin vivo. J. Pharmacol. Exp. Ther.137, 47–55 (1962).
Wexler, B. C., G. W. Kittinger: Myocardial necrosis in the rat: serum enzymes, adrenal steroid and histopathological alterations. Circulat. Res.13, 159–171 (1963).
Wurzburg, U., N. Henrich, B. H. Orth, H. Lang: Quantitative determination of creatinkinase isoenzyme catalytic concentrations in serum using immunological methods. J. Clin. Chem. Clin. Biochem.15, 131–137 (1977).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Genovese, A., Chiariello, M., De Alfieri, W. et al. Production of cardiac lesions with tyramine in intact rats. Basic Res Cardiol 78, 289–297 (1983). https://doi.org/10.1007/BF01907438
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF01907438